Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – The global longevity biotech market exploded from $27.15 billion in 2024 toward $46.61 billion by 2033 at 6.5% CAGR[1], as the $101 million XPRIZE Healthspan competition awarded milestone prizes to 40 teams from 600 global competitors earlier this year[2]. The biotech sector has been delivering new answers for aging, with new developments coming from Avant Technologies, Inc. (OTCQB: AVAI), Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), Amgen Inc. (NASDAQ: AMGN), Lineage Cell Therapeutics, Inc. (NYSE-American: LCTX), and Arcutis Biotherapeutics (NASDAQ: ARQT).
Anti-aging drugs market rockets from $79 million to $2.8 billion by 2040 at 27% CAGR[3] while senolytics and anti-aging pharmaceuticals command $8.72 billion by 2034 with Asia Pacific accelerating at 8.8% growth[4]. Americans over 65 command $22,356 in annual healthcare spending per person versus just $4,217 for children[5] as demographic pressures create unprecedented demand for breakthrough longevity therapeutics.
Avant Technologies, Inc. (OTCQB: AVAI) has executed a strategic pivot into the high-growth longevity biotechnology sector through a transformative joint venture with Singapore-based Austrianova (SGAustria Pte. Ltd.), establishing Klothonova, Inc. as a 50/50 partnership focused on pioneering cell-based therapies utilizing encapsulated Klotho-producing cells. This agreement positions Avant at the forefront of anti-aging therapeutics by leveraging Austrianova's proprietary cell-encapsulation technology and decades of expertise in cell biology and GMP-grade manufacturing.
The joint venture targets multiple lucrative therapeutic areas including Alzheimer's disease, heart disease, cancer, kidney disease, and other age-related conditions through innovative treatments based on Klotho protein overexpression. Austrianova brings substantial intellectual property backed by over 50 peer-reviewed publications and established partnerships with global pharmaceutical companies, while Avant provides capital and operational resources to accelerate Klothonova's development pipeline.
"We are thrilled to partner with Austrianova, whose world-class expertise in cell encapsulation and GMP manufacturing complements our vision for advancing transformative healthcare solutions," said Chris Winter, CEO at Avant Technologies. "Klothonova represents a significant step toward addressing some of the most pressing medical challenges of our time."
The scientific foundation appears compelling based on extensive research demonstrating Klotho's therapeutic potential. Studies show that higher Klotho levels correlate with up to 30% increased lifespan, while individuals with lowest Klotho levels had 31% higher mortality rates than those with higher levels. Critically, natural Klotho levels drop by 50% after age 40, creating substantial therapeutic opportunities for intervention.
Klotho, discovered in 1997 and primarily produced in kidneys and brain tissue, functions as a crucial "longevity protein" that modulates aging processes while affecting brain, heart, kidneys, and immune function simultaneously. Research has linked Klotho to improved cognitive function, cardiovascular health, and kidney function, with demonstrated potential in combating age-related diseases.
"This joint venture with Avant Technologies allows us to combine our proprietary technologies with Avant's resources to accelerate the development of Klotho-based therapies," added Brian Salmons, CEO at Austrianova. "We are excited about the potential to improve patient outcomes and promote healthier, longer lives."
The market opportunity appears substantial across multiple therapeutic areas. The global Alzheimer's disease market is projected to reach $32.8 billion by 2033, while cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. Austrianova's proven Cell-in-a-Box® technology with 30+ years of development enables sustained, controlled delivery of Klotho-producing cells through established GMP manufacturing capabilities.
This strategic transformation positions Avant within the rapidly expanding longevity biotechnology sector, with Klothonova's exclusive licensing arrangements and equal ownership structure creating multiple potential value creation pathways as Klotho-based treatments advance toward clinical validation and commercialization across global markets.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Lexicon Pharmaceuticals (NASDAQ: LXRX) has demonstrated meaningful pain reduction with its investigational AAK1-inhibitor pilavapadin, achieving a two-point reduction from baseline in average daily pain scores by week 11 in adults with diabetic peripheral neuropathic pain. The Phase 2b PROGRESS study enrolled 496 adult patients and showed nominally significant separation from placebo in post-hoc analysis of the 10 mg dose arms. Data presented at the European Association for the Study of Diabetes and NEUROdiab Annual Meetings support pilavapadin's potential as the first non-opioid oral medication for this condition in over two decades.
"The data presented at NEUROdiab and EASD provide additional support for our understanding of pilavapadin's profile, as well as its potential as a much-needed new therapy for DPNP," said Suma Gopinathan, Senior Vice President of Discovery at Lexicon Pharmaceuticals. "Pilavapadin has potential to become the first non-opioid, oral medication approved for DPNP in over two decades. We look forward to Phase 3 trials for this potential new therapy."
The company has identified pilavapadin 10 mg once daily as the most clinically meaningful dose based on study results, with the treatment demonstrating good tolerability and minimal discontinuations. Lexicon plans to advance pilavapadin into Phase 3 trials to address the significant unmet need among approximately nine million patients suffering from diabetic peripheral neuropathic pain in the United States.
Amgen (NASDAQ: AMGN) has reported positive long-term results from its Phase 3 ASCEND study evaluating rocatinlimab in approximately 2,600 patients with moderate to severe atopic dermatitis, with the majority of patients maintaining therapeutic benefit at one year of treatment. The ongoing extension study demonstrated continued efficacy across measures of skin clearance, itch, disease extent and severity, with low discontinuation rates due to adverse events. Rocatinlimab represents a potential first-in-class T-cell rebalancing therapy targeting the OX40 receptor, with possible maintenance dosing as infrequently as every eight weeks.
"Atopic dermatitis is a heterogeneous disease where many patients still lack adequate control with current therapies," said Jay Bradner, M.D., Executive Vice President of Research and Development at Amgen. "These findings add to our understanding of the role OX40 inhibition can play in addressing the underlying drivers of this chronic disease and provide further information on rocatinlimab's durability of response and long-term safety profile, which we will continue to monitor."
The ASCEND study continues to evaluate long-term safety and efficacy for up to 104 weeks in adult and adolescent patients, as part of Amgen's comprehensive ROCKET Phase 3 program developed in collaboration with Kyowa Kirin. Amgen and Kyowa Kirin plan to share full results at an upcoming medical congress or in a peer-reviewed publication as they advance this potential breakthrough therapy for atopic dermatitis patients.
Lineage Cell Therapeutics (NYSE American: LCTX) has secured a research collaboration with William Demant Invest worth up to $12 million over three years to advance its ReSonance (ANP1) auditory neuronal cell transplant for hearing loss treatment. The partnership will jointly conduct preclinical development activities including cell manufacturing, proof-of-concept studies, and regulatory strategy to support a potential IND/CTA filing. ReSonance represents Lineage's first internally-developed cell transplant program, targeting the estimated 2.5 billion people expected to experience some degree of hearing loss by 2050 according to the World Health Organization.
"ReSonance is our first internally-developed cell transplant program and highlights the efficiency and breadth of our technology platform," said Brian Culley, CEO of Lineage Cell Therapeutics. "Over a short period of time and with a modest initial, incremental investment, we advanced the ANP1 product concept through successful manufacture of the desired cell type, generated new intellectual property, and advanced into initial preclinical testing. This partnership will allow us to integrate the hearing loss research expertise of Eriksholm Research Centre with the manufacturing and cell transplant expertise of the Lineage team to explore the potential of a differentiated cell transplant, and position this therapy for initial clinical development."
The collaboration leverages William Demant Invest's expertise in hearing healthcare through its subsidiary Eriksholm Research Centre, part of Oticon A/S within the Demant Group. Lineage continues to advance its neuroscience-focused pipeline, which includes OpRegen in Phase 2a development with Roche and Genentech for age-related macular degeneration, positioning the company as a leader in "off-the-shelf" cell therapies for serious neurological conditions.
Arcutis Biotherapeutics (NASDAQ: ARQT) has achieved its fifth FDA approval for ZORYVE in less than three years, with the FDA approving roflumilast topical foam 0.3% for treating plaque psoriasis of the scalp and body in patients 12 years and older. The once-daily, steroid-free topical treatment addresses a significant market opportunity, as nearly 9 million Americans live with plaque psoriasis and over half experience scalp involvement. Clinical trials demonstrated significant improvements in both skin clearance and rapid itch relief across all efficacy endpoints, with the foam formulation offering convenient application for hair-bearing areas.
"Individuals living with psoriasis, a chronic inflammatory skin disease, want treatments that are not only safe and effective for long-term use but also convenient," said Frank Watanabe, CEO of Arcutis Biotherapeutics. "With approval for cream and now the foam formulations, individuals and clinicians can choose their preferred administration of ZORYVE with powerful, long-term relief of plaques and itch anywhere on the body, including hair-bearing areas, with no limitation on duration of use. This is the fifth approval for ZORYVE in less than three years and furthers our mission to deliver new treatment options that address the urgent needs of individuals suffering from chronic inflammatory skin diseases."
ZORYVE foam is now widely available through key wholesaler and dermatology pharmacy channels, with Arcutis providing predictable access through its ZORYVE Direct Program. The company's expanding ZORYVE portfolio now covers three major inflammatory dermatoses including atopic dermatitis, seborrheic dermatitis, and plaque psoriasis, positioning Arcutis as a leader in next-generation topical phosphodiesterase-4 inhibitor therapies.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
Baystreet.ca
[email protected]
(250) 999-4849
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
--
SOURCES CITED
1. https://www.businessresearchinsights.com/market-reports/longevity-biotech-market-118596
2. https://www.xprize.org/prizes/healthspan/articles/101m-xprize-healthspan-awards-first-milestone-winners-driving-toward-revolutionary-healthy-aging-advances
3. https://www.rootsanalysis.com/reports/anti-aging-therapeutics-market.html
4. https://www.precedenceresearch.com/senolytics-and-anti-aging-pharmaceuticals-market
5. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
